Skip to content

ZIVO BIOSCIENCE, INC.: 10-Q filed 2025-08-14

What ZIVO BIOSCIENCE, INC. reported in its quarterly report filed 2025-08-14 (fiscal Q2 2025): 32 published measures, 93 facts as tagged in accession 0001654954-25-009650.

This filing

Form
10-Q (quarterly report)
Filed
2025-08-14
Fiscal period
fiscal Q2 2025
Accession
0001654954-25-009650 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ZIVO BIOSCIENCE, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-30703,327USD
At 2024-12-311,643,122USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-06-303,244,073USD
At 2024-12-312,158,020USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-06-30-2,540,746USD
At 2025-03-31-1,617,277USD
At 2024-12-31-514,898USD
At 2024-06-30-2,295,614USD
At 2024-03-31-2,268,900USD
At 2023-12-31-2,205,844USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-1,640,232USD91
2025-01-01 to 2025-06-30-5,851,418USD181
2024-04-01 to 2024-06-30-8,236,368USD91
2024-01-01 to 2024-06-30-9,514,854USD182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-1,906,648USD181
2024-01-01 to 2024-06-30-2,322,772USD182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2025-04-01 to 2025-06-3053,400USD91
2025-01-01 to 2025-06-3053,400USD181
2024-04-01 to 2024-06-300USD91
2024-01-01 to 2024-06-3035,720USD182

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-04-01 to 2025-06-3053,400USD91
2025-01-01 to 2025-06-3053,400USD181
2024-04-01 to 2024-06-300USD91
2024-01-01 to 2024-06-3035,720USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-06-30374,029USD181
2024-01-01 to 2024-06-302,050,858USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-06-300USD181
2024-01-01 to 2024-06-300USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-142,817,969USD
At 2024-12-31-136,966,551USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-04-01 to 2025-06-303,810,065shares91
2025-01-01 to 2025-06-303,780,238shares181
2024-04-01 to 2024-06-302,961,606shares91
2024-01-01 to 2024-06-302,875,631shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.43USD/shares91
2025-01-01 to 2025-06-30-1.55USD/shares181
2024-04-01 to 2024-06-30-2.78USD/shares91
2024-01-01 to 2024-06-30-3.31USD/shares182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-1,632,872USD91
2025-01-01 to 2025-06-30-5,841,659USD181
2024-04-01 to 2024-06-30-8,229,602USD91
2024-01-01 to 2024-06-30-9,505,441USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-06-30409,894USD
At 2024-12-311,635,442USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2025-04-01 to 2025-06-307,360USD91
2025-01-01 to 2025-06-309,759USD181
2024-04-01 to 2024-06-306,766USD91
2024-01-01 to 2024-06-309,413USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-06-302,959,588USD
At 2024-12-312,041,823USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-06-30860,939USD
At 2024-12-31547,090USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-04-01 to 2025-06-301,650,794USD91
2025-01-01 to 2025-06-305,859,581USD181
2024-04-01 to 2024-06-308,229,602USD91
2024-01-01 to 2024-06-309,517,943USD182

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-04-01 to 2025-06-3017,922USD91
2025-01-01 to 2025-06-3017,922USD181
2024-04-01 to 2024-06-300USD91
2024-01-01 to 2024-06-3012,502USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-04-01 to 2025-06-30479,657USD91
2025-01-01 to 2025-06-303,248,892USD181
2024-04-01 to 2024-06-302,252,325USD91
2024-01-01 to 2024-06-302,565,092USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-06-303,817,005shares
At 2024-12-313,621,335shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-06-309,823USD
At 2024-12-311,542,442USD
At 2024-06-302,466USD
At 2023-12-31274,380USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-06-30140,273,406USD
At 2024-12-31136,448,032USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-06-30285,753USD
At 2024-12-310USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-06-30300,742USD
At 2024-12-310USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-06-301,433,953USD
At 2024-12-311,096,179USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-06-30365,707USD
At 2024-12-3190,789USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-301,171,137USD91
2025-01-01 to 2025-06-302,610,689USD181
2024-04-01 to 2024-06-305,977,277USD91
2024-01-01 to 2024-06-306,952,851USD182

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-06-308,242USD181
2024-01-01 to 2024-06-308,223USD182

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2025-01-01 to 2025-06-300USD181
2024-01-01 to 2024-06-300USD182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-04-01 to 2025-06-30150,000USD91
2025-01-01 to 2025-06-30150,000USD181
2024-01-01 to 2024-06-301,763,325USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-06-30313,849USD181
2024-01-01 to 2024-06-30100,379USD182

Inspect the source

Entity
ZIVO BIOSCIENCE, INC. / CIK 0001101026
Captured
2026-09-20T05:23:02.675Z
SEC response SHA-256
a67c6f73387834b08f1985c02ad3ba915b8082582e19652219d78b25a60d946c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001101026.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))